Pembrolizumab + Nab-paclitaxel + Paclitaxel + Gemcitabine + Carboplatin + Normale Saline Solution
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Triple Negative Breast Cancer (TNBC)
Conditions
Triple Negative Breast Cancer (TNBC)
Trial Timeline
Jul 27, 2016 → Oct 30, 2023
NCT ID
NCT02819518About Pembrolizumab + Nab-paclitaxel + Paclitaxel + Gemcitabine + Carboplatin + Normale Saline Solution
Pembrolizumab + Nab-paclitaxel + Paclitaxel + Gemcitabine + Carboplatin + Normale Saline Solution is a phase 3 stage product being developed by Merck for Triple Negative Breast Cancer (TNBC). The current trial status is completed. This product is registered under clinical trial identifier NCT02819518. Target conditions include Triple Negative Breast Cancer (TNBC).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02819518 | Phase 3 | Completed |
Competing Products
20 competing products in Triple Negative Breast Cancer (TNBC)